Vessels, Voltage and Voices: Can Tadalafil Tackle Cognitive Deficits in Schizophrenia?

Medically reviewed by PChina Jin LI (李锦) Institute of toxicology, Academy of Military Medical Sciences, Beijing

Introduction

Cognitive impairment in schizophrenia is the elephant in the psychiatric room. It doesn’t respond well to antipsychotics, it rarely remits on its own, and for many patients, it’s the most disabling part of the illness. Attention, working memory, executive function all take a hit, often before the first psychotic break, and often persisting long after delusions and hallucinations subside. Yet despite decades of research, we still lack a pharmacological intervention that meaningfully improves cognition in this population.

What if part of the problem isn’t purely neurochemical, but vascular? That’s the idea behind a growing body of work exploring cerebral perfusion, endothelial function, and small-vessel pathology in schizophrenia. Some researchers argue that impaired blood flow and oxygenation, especially in the prefrontal cortex, may underlie or exacerbate cognitive decline. If that’s true, then perhaps a drug class best known for treating erectile dysfunction might have a role to play in brain health.

Enter tadalafil, a long-acting PDE5 inhibitor with the unusual ability to cross the blood–brain barrier and improve regional cerebral blood flow (CBF). Originally developed for vascular conditions, it’s now being studied for effects on cognition, mood, and even neuroinflammation. A few human studies and early-phase trials suggest it might do more than just improve circulation, it might actually help repair or stabilize cognitive systems in vulnerable brains. Could this approach be relevant for schizophrenia? And if so, how close are we to answering that question in the clinic? This article explores the rationale, evidence, and open questions behind the neurovascular hypothesis of cognition, and whether tadalafil deserves a seat at the table.

Cognitive Impairment in Schizophrenia and the Vascular Hypothesis

Cognition is increasingly recognized as the unmet frontier in schizophrenia treatment. While antipsychotics can manage positive symptoms like hallucinations, delusions, disorganized speech, they do little for the executive dysfunction, slowed processing, and impaired attention that often determine long-term outcomes. For many patients, these cognitive deficits are present from early stages, sometimes predating psychosis, and persist even in remission. Worse, they’re closely tied to functional disability: the ability to live independently, maintain employment, and form relationships. Despite years of drug development, cognitive enhancement in schizophrenia remains elusive. Attempts to tweak dopaminergic or cholinergic systems have shown limited success, and newer approaches targeting glutamate or nicotinic receptors remain experimental. This has led researchers to rethink not just the neurotransmitters involved, but the biological foundations of cognitive dysfunction.

One of the more intriguing theories is that schizophrenia involves not only synaptic and neurodevelopmental abnormalities, but also vascular dysregulation. Postmortem and imaging studies have found signs of cerebral hypoperfusion, small-vessel pathology, and blood–brain barrier compromise, especially in the prefrontal cortex and hippocampus, regions tightly linked to cognitive processing. In this model, reduced oxygen and nutrient delivery may compound underlying circuit dysfunction, limiting plasticity and slowing cortical recovery.

It’s here that vasoactive agents, like PDE5 inhibitors, enter the picture. By improving endothelial function and microvascular blood flow, they may offer a novel route to enhancing neural efficiency and cognitive reserve. This doesn’t mean tadalafil would act as a “smart drug” in the classic sense, but rather as a metabolic and hemodynamic support, aimed at the structural bottlenecks that hold cognition back in schizophrenia.

Tadalafil Pharmacokinetics, BBB Penetration and Neural Perfusion

Tadalafil isn’t your average cognitive candidate. Originally designed to treat erectile dysfunction and later benign prostatic hyperplasia, it owes its popularity to vasodilation, smooth muscle relaxation, and an unusually long half-life: around 17.5 hours. This makes it ideal for steady vascular effects, with less of the timing pressure seen with sildenafil or vardenafil. But what’s less appreciated outside urology is how well tadalafil distributes beyond the periphery, including penetration into the central nervous system.

Unlike many other PDE5 inhibitors, tadalafil is lipophilic enough to cross the blood–brain barrier (BBB) in measurable quantities, and long-acting enough to maintain central exposure without pulsatile peaks. Once inside the CNS, it inhibits phosphodiesterase type 5, an enzyme that breaks down cyclic GMP (cGMP). Elevated cGMP levels lead to vasodilation in cerebral arterioles, enhanced neuronal signaling, and possibly improved perfusion in functionally impaired brain regions. These effects aren’t just theoretical. Several small neuroimaging studies in humans have shown that daily low-dose tadalafil increases regional cerebral blood flow, particularly in areas like the prefrontal cortex and anterior cingulate cortex, regions consistently implicated in working memory, attention, and emotional regulation. Importantly, this isn’t simply about more blood for blood’s sake. Improved perfusion may restore neurovascular coupling, optimize metabolic supply, and support the plasticity needed for cognitive rehabilitation in chronic mental illness.

In the context of schizophrenia, where neurovascular dysfunction, oxidative stress, and glial inflammation often coexist, tadalafil’s ability to act at the interface of vascular and synaptic integrity makes it more than a repurposing curiosity. It becomes a candidate for a system-level intervention—one that aligns with both the biological underpinnings and the day-to-day impairments seen in cognitive subtypes of the disorder.

Human Signal: Low-Dose Tadalafil Increased CBF & Cognition

The next leap in understanding tadalafil’s brain effects will likely come from structured interventional trials, and the ETLAS-2 protocol, launched in 2024, is a prime example of how far the field has moved from urology. Though not designed specifically for psychiatric populations, ETLAS-2 explores the effect of daily 5 mg tadalafil for 12 weeks on cognitive performance, cerebrovascular reactivity (CVR), and regional CBF in older adults with cerebral small-vessel disease, a model with overlapping features of schizophrenia, especially regarding microvascular pathology.

What makes ETLAS-2 particularly relevant is its use of multimodal endpoints: neuroimaging (including ASL-fMRI), cognitive batteries, and blood-based biomarkers of endothelial and inflammatory activity. This trial may not address schizophrenia directly, but its methodology offers a clear template: well-defined inclusion criteria, tight mechanistic hypotheses, and real-world functional outcomes. There’s also a growing interest in pairing tadalafil treatment with electrophysiological markers, especially mismatch negativity (MMN), a well-validated EEG signal that reflects early auditory discrimination and NMDA receptor integrity. In schizophrenia, MMN is often blunted, correlating with both cognitive decline and functional impairment. It is also sensitive to pharmacologic intervention, making it an attractive candidate for tracking subtle gains that might precede behavioral improvements.

Incorporating MMN as a co-primary or exploratory endpoint in future schizophrenia trials of tadalafil could bridge the gap between vascular modulation and cognitive recovery, offering a noninvasive way to track early central effects, long before symptom scales shift. If improved perfusion and reduced neuroinflammation can restore MMN amplitude, that would represent not just a vascular effect, but a neural one.

Ongoing Trials: ETLAS-2 Design and Schizophrenia-Specific MMN Endpoints

Cognition doesn’t exist in a vacuum. In schizophrenia, it often suffers under the weight of neuroinflammatory load, a silent but persistent storm of cytokines, oxidative stress, and glial dysregulation. Among these, interleukin-6 (IL-6) has drawn particular attention, repeatedly linked to cognitive decline, negative symptoms, and poor functional outcomes. IL-6 crosses the blood–brain barrier and can interfere with synaptic plasticity, especially in the prefrontal cortex.

In 2019, a study by Urios et al. took this connection further. Patients with LUTS and comorbid erectile dysfunction, many of whom also reported cognitive complaints—received daily tadalafil for 12 weeks. The treatment led to a statistically significant reduction in IL-6, alongside improvements in cognition and mismatch negativity (MMN) amplitude. Though not a schizophrenia cohort, the findings point to a shared pathway: when inflammation drops, cognitive processing improves.

MMN, often described as the brain’s early warning system for sensory changes, is notably attenuated in schizophrenia and correlates with poor executive functioning. Its recovery has been proposed as an indicator of restored neural circuit efficiency, especially in early auditory and frontal systems. The fact that MMN was enhanced in the Urios study, alongside reduced IL-6, suggests that tadalafil’s anti-inflammatory effects may be just as important as its vascular ones. This dual action on blood flow and immune tone sets tadalafil apart from purely dopaminergic or glutamatergic strategies. It may be working not at the synapse, but upstream, creating the biological conditions for more resilient and efficient neural signaling.

It’s an attractive theory: lower inflammation, improve perfusion, restore circuit responsiveness. And for a population long underserved by traditional approaches, that multi-pronged strategy might be exactly what’s needed.

Mechanistic Angles: Neuroinflammation, IL-6 and Mismatch Negativity Recovery

Despite the promising mechanistic and early clinical data, translating tadalafil into a viable adjunctive treatment for cognitive deficits in schizophrenia will require careful trial design—and a clear-eyed view of its limitations.

First, there’s the question of dosing. Most vascular and sexual medicine trials use 5 mg daily, a dose that offers sustained PDE5 inhibition with good tolerability. That same dose has been applied in cerebral perfusion studies, including ETLAS-2. However, it remains unclear whether this is optimal for cognitive targets, or whether lower, more CNS-selective doses might be safer in psychiatric populations with cardiovascular vulnerability. Trials will need to balance central effects with risks like orthostatic hypotension, especially in patients on antipsychotics or antihypertensives.

Second, inclusion criteria must evolve. Not all patients with schizophrenia have significant cognitive impairment, and not all cognitive deficits share the same etiology. Future studies should stratify participants by cognitive phenotype, baseline MMN amplitude, or even inflammatory markers such as IL-6 or CRP. These measures may help identify “vascular-inflamed” subgroups most likely to benefit from tadalafil’s dual action on perfusion and immune tone.

Third, outcome measures must go beyond standard cognitive tests. While batteries like MATRICS remain useful, integrating neuroimaging endpoints (CBF, ASL-fMRI), electrophysiological markers (MMN, P300), and functionally relevant cognitive metrics will give a more complete picture of drug impact. Duration matters too. Trials shorter than 8–12 weeks may miss delayed-onset effects tied to structural or inflammatory remodeling.

Finally, trial design must reflect real-world complexity. Many schizophrenia patients are on polypharmacy regimens. Tadalafil’s favorable safety profile is a plus, but potential interactions, especially with nitrates, alpha-blockers, or strong CYP3A4 inhibitors, must be monitored.

In short, if the goal is a meaningful, mechanistically informed trial, the roadmap is there — it just needs to be followed.

Practical Considerations and Future RCT Design

The idea of using tadalafil, best known as a treatment for erectile dysfunction, as a cognitive adjunct in schizophrenia may seem like a stretch. But when viewed through the lens of neurovascular physiology, immune modulation, and circuit-level plasticity, it begins to look much more plausible. Cognitive impairment in schizophrenia has always been a complex target, deeply resistant to single-pathway interventions. What tadalafil offers is a multi-dimensional mechanism: increasing cerebral blood flow, reducing pro-inflammatory cytokines like IL-6, and potentially restoring electrophysiological markers like mismatch negativity.

This isn’t a repurposing gimmick. It’s a strategy grounded in emerging systems neuroscience, supported by early-phase human data and carefully designed trials in vascular cognitive syndromes. The ETLAS-2 protocol may not answer every question, but it models exactly the kind of structured, biomarker-informed approach that psychiatry needs.

Of course, we’re not there yet. Tadalafil won’t replace cognitive remediation or fix cognition on its own. But it may unlock a more favorable physiological state, one in which the brain is better equipped to respond to behavioral and pharmacological input. If the next generation of trials can identify the right patients (those with inflammatory, vascular, and electrophysiological signatures of dysfunction) we may finally move closer to addressing what has long been the most neglected symptom domain in schizophrenia.

Not a miracle drug. But a gateway, perhaps, to something better.

Take-Home Points

Tadalafil, a long-acting PDE5 inhibitor, shows growing potential beyond its traditional use. In schizophrenia, where cognitive impairment remains a major unmet need, its ability to enhance cerebral blood flow, reduce IL-6, and restore mismatch negativity (MMN) may offer a novel multimodal approach. While evidence is still early-stage, findings from perfusion and inflammation studies support its mechanistic plausibility.

Importantly, tadalafil’s favorable pharmacokinetics and central activity make it suitable for longer-term cognitive trials, especially when guided by biomarkers like MMN or CRP. Though not a primary treatment, it may serve as a supportive agent, improving the brain’s physiological environment for plasticity and recovery. Well-designed RCTs are now needed to clarify its role and identify who might benefit most.